Demodex Blepharitis

1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Glaukos
GlaukosALISO VIEJO, CA
1 program
1
GLK-321 low dose BIDPhase 21 trial
Active Trials
NCT07400965RecruitingEst. Nov 2026
Thea Pharma
Thea PharmaMA - Waltham
1 program
BlephademodexN/A1 trial
Active Trials
NCT04780165CompletedEst. May 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GlaukosGLK-321 low dose BID
Thea PharmaBlephademodex

Clinical Trials (2)

NCT07400965GlaukosGLK-321 low dose BID

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

Start: Dec 2025Est. completion: Nov 2026
Phase 2Recruiting

Efficacy and Tolerability of Blephademodex Wipes

Start: Sep 2019Est. completion: May 2020
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
2 companies competing in this space